NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) issued its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.83) by $0.03. The biopharmaceutical company earned $4.20 million during the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative return on equity of 30.79% and a negative net margin of 353.57%. The business's revenue was up 27.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

14 equities research analysts have issued 1 year price objectives for Acceleron Pharma's stock. Their forecasts range from $45.00 to $138.00. On average, they expect Acceleron Pharma's stock price to reach $79.23 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Media coverage about XLRN stock has been trending very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Acceleron Pharma.

Acceleron Pharma saw a decrease in short interest in the month of December. As of December 13th, there was short interest totalling 4,230,000 shares, a decrease of 6.8% from the November 28th total of 4,540,000 shares. Based on an average trading volume of 359,500 shares, the short-interest ratio is currently 11.8 days. Approximately 9.4% of the shares of the stock are sold short. View Acceleron Pharma's Current Options Chain.

Some companies that are related to Acceleron Pharma include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (GILD), LogicBio Therapeutics (LOGC), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Incyte (INCY), Intel (INTC), NVIDIA (NVDA) and Corcept Therapeutics (CORT).

Acceleron Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.91%), California Public Employees Retirement System (0.19%), Rhenman & Partners Asset Management AB (0.19%), Neville Rodie & Shaw Inc. (0.04%), Wealthstreet Investment Advisors LLC (0.04%) and Zeke Capital Advisors LLC (0.02%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Neville Rodie & Shaw Inc., Zeke Capital Advisors LLC, Nisa Investment Advisors LLC and Wealthstreet Investment Advisors LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, California Public Employees Retirement System, Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $76.40.

Acceleron Pharma has a market capitalization of $4.06 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]